Apple event recap: Everything announced New AirPods for $179 New 16-inch MacBook Pro for $2,499 Disney delays Marvel movies Walmart Black Friday deals start Nov. 3 New Microsoft Office rollout

AstraZeneca's COVID vaccine is safe, says European regulator after blood clot concerns

The vaccine is not associated with an increase in the overall risk of blood clots, the European Medicines Agency found.

gettyimages-1300310338

The AstraZeneca COVID-19 vaccine is not associated with an increased risk of blood clots, it has been found.

Dan Kitwood/Getty Images
For the most up-to-date news and information about the coronavirus pandemic, visit the WHO and CDC websites.

The European Medicines Agency concluded its preliminary review of AstraZeneca's COVID-19 vaccine of AstraZeneca's COVID-19 vaccine Thursday, finding that the drug is not associated with an increase in the overall risk of blood clots in those who receive it.

The finding comes after the deaths of patients in Norway and in Denmark who had begun receiving the vaccine. Earlier this week, France, Germany, Italy and Spain joined Austria and other EU nations that had paused their rollouts of the AstraZeneca vaccine pending the EMA's findings.

See also: How to get a COVID-19 vaccine appointment

"The benefits of the vaccine in combating the still widespread threat of COVID-19 (which itself results in clotting problems and may be fatal) continue to outweigh the risk of side effects," the EMA wrote. Additionally, the EMA found no evidence of a problem related to specific batches of the vaccine, or to particular manufacturing sites.

However, the organization does note that the vaccine may be associated with very rare cases of blood clots associated with thrombocytopenia, a condition that causes an underlying low blood platelet count. Issues with the vessels that drain blood from the brain (CVST) were also reported.

"These are rare cases," the EMA writes, noting that it had identified just 25 total instances of clotting out of 20 million people who have received the AstraZeneca vaccine in the UK and EEA.

"A causal link with the vaccine is not proven, but is possible and deserves further analysis," the EMA says.

The EMA notes that almost all cases of clotting were in women under the age of 55. The organization advises patients who receive the AstraZeneca vaccine to seek prompt medical attention if they experience breathlessness, pain in the chest or stomach, swelling or coldness in the arm or leg, severe or worsening headache, persistent bleeding, multiple small bruises, reddish or purplish spots on the skin or blood blisters beneath the skin.

The information contained in this article is for educational and informational purposes only and is not intended as health or medical advice. Always consult a physician or other qualified health provider regarding any questions you may have about a medical condition or health objectives.